ADMA Biologics Inc
General ticker "ADMA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $4.6B
ADMA Biologics Inc follows the US Stock Market performance with the rate: 62.6%.
Estimated limits based on current volatility of 2.3%: low 17.35$, high 18.16$
Factors to consider:
- US accounted for 94.8% of revenue in the fiscal year ended 2023-12-31
- Current price 194.1% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [3.05$, 6.03$]
- 2024-12-30 to 2025-12-30 estimated range: [3.11$, 6.20$]
Financial Metrics affecting the ADMA estimates:
- Negative: Non-GAAP EPS, $ of 0 <= 0.10
- Negative: Operating cash flow per share per price, % of 1.00 <= 2.35
- Negative: negative Net income
- Positive: 1.03 < Operating profit margin, % of 8.38
- Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
- Negative: Industry operating profit margin (median), % of -98.30 <= 2.14
- Negative: Industry earnings per price (median), % of -26.04 <= 1.31
Short-term ADMA quotes
Long-term ADMA plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $80.94MM | $154.08MM | $258.21MM |
| Operating Expenses | $139.32MM | $193.44MM | $236.58MM |
| Operating Income | $-58.37MM | $-39.37MM | $21.63MM |
| Non-Operating Income | $-13.27MM | $-26.54MM | $-49.87MM |
| Interest Expense | $13.06MM | $19.28MM | $25.03MM |
| R&D Expense | $3.65MM | $3.61MM | $3.30MM |
| Income(Loss) | $-71.65MM | $-65.90MM | $-28.24MM |
| Profit(Loss) | $-71.65MM | $-65.90MM | $-28.24MM |
| Stockholders Equity | $141.17MM | $151.97MM | $135.21MM |
| Assets | $276.25MM | $348.46MM | $329.18MM |
| Operating Cash Flow | $-112.37MM | $-59.51MM | $8.80MM |
| Capital expenditure | $13.51MM | $13.91MM | $4.98MM |
| Investing Cash Flow | $-13.51MM | $-13.91MM | $-4.98MM |
| Financing Cash Flow | $121.05MM | $108.85MM | $-38.99MM |
| Earnings Per Share* | $-0.61 | $-0.43 | $-0.13 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.